189 related articles for article (PubMed ID: 22033412)
21. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
[TBL] [Abstract][Full Text] [Related]
22. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
[TBL] [Abstract][Full Text] [Related]
23. Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S
Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580
[TBL] [Abstract][Full Text] [Related]
24. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
Paquette RL; Nicoll J; Chalukya M; Elashoff D; Shah NP; Sawyers C; Spiteri E; Nanjangud G; Rao PN
Cancer Genet; 2011 Jul; 204(7):392-7. PubMed ID: 21872826
[TBL] [Abstract][Full Text] [Related]
25. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.
Spensberger D; Delwel R
FEBS Lett; 2008 Aug; 582(18):2761-7. PubMed ID: 18619962
[TBL] [Abstract][Full Text] [Related]
26. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and biological characteristics of childhood acute myeloid leukemia with EVI1 gene positive expression].
Jiang M; Li XQ; Hu D; Qiu YN; Zhang ZQ; Zhang BY; Han J; Jin RM
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):129-34. PubMed ID: 24568904
[TBL] [Abstract][Full Text] [Related]
28. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
29. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
[TBL] [Abstract][Full Text] [Related]
31. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells.
Kustikova OS; Schwarzer A; Stahlhut M; Brugman MH; Neumann T; Yang M; Li Z; Schambach A; Heinz N; Gerdes S; Roeder I; Ha TC; Steinemann D; Schlegelberger B; Baum C
Leukemia; 2013 Apr; 27(5):1127-38. PubMed ID: 23212151
[TBL] [Abstract][Full Text] [Related]
32. Acute panmyelosis with myelofibrosis with EVI1 amplification.
Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
[TBL] [Abstract][Full Text] [Related]
33. The role of EVI1 in myeloid malignancies.
Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
[TBL] [Abstract][Full Text] [Related]
34. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.
Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R
Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813
[TBL] [Abstract][Full Text] [Related]
35. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
[TBL] [Abstract][Full Text] [Related]
36. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
[TBL] [Abstract][Full Text] [Related]
37. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
38. The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity.
Kilbey A; Alzuherri H; McColl J; Calés C; Frampton J; Bartholomew C
Br J Haematol; 2005 Sep; 130(6):902-11. PubMed ID: 16156860
[TBL] [Abstract][Full Text] [Related]
39. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
40. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.
Spensberger D; Vermeulen M; Le Guezennec X; Beekman R; van Hoven A; Bindels E; Stunnenberg H; Delwel R
Biochemistry; 2008 Jun; 47(24):6418-26. PubMed ID: 18500823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
